Literature DB >> 27115200

Renal outcomes in mixed proliferative and membranous lupus nephritis (Class III/IV + V): A long-term observational study.

Hidekazu Ikeuchi1, Keiju Hiromura1, Ken Kayakabe1, Kadiombo Anastasie Tshilela1, Kazuhiko Uchiyama1, Hiroko Hamatani1, Toru Sakairi1, Yoriaki Kaneko1, Akito Maeshima1, Yoshihisa Nojima1.   

Abstract

OBJECTIVES: In this study, we aimed to assess the effect of combination of proliferative and membranous lesions (Class III + V or IV + V) on renal outcomes as an independent category distinct from Class III and IV.
METHODS: We retrospectively analyzed 103 Japanese patients (14 male and 89 female) with Class III/IV LN, with or without Class V, who underwent renal biopsy and were treated at our institution. Renal endpoint was defined as doubling of serum creatinine or end-stage renal disease (ESRD).
RESULTS: The number of patients in each group was as follows: pure Class III/IV, 81 patients and mixed Class III/IV + V, 22 patients. During a median follow-up period of 125.0 months, 10 patients developed renal endpoint: five had Class III/IV LN and five had a combination of Class III/IV + V. Kaplan-Meier analyses demonstrated that patients with mixed Class III/IV + V LN had significantly poorer renal outcomes than patients with Class III/IV LN. Multivariate Cox regression analyses identified serum creatinine, active and chronic lesions (A/C), and mixed Class III/IV + V) as independent risk factors for poor renal outcomes.
CONCLUSIONS: This study demonstrated a combination of proliferative and membranous LN (ISN/RPS Class III/IV + V) predicts poor renal outcomes.

Entities:  

Keywords:  ISN/RPS classification; Lupus nephritis; Renal outcome; Systemic lupus erythematosus

Mesh:

Year:  2016        PMID: 27115200     DOI: 10.3109/14397595.2016.1158896

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  6 in total

Review 1.  The role of osteopontin in kidney diseases.

Authors:  Beata Kaleta
Journal:  Inflamm Res       Date:  2018-11-19       Impact factor: 4.575

2.  Cleaved Form of Osteopontin in Urine as a Clinical Marker of Lupus Nephritis.

Authors:  Koji Kitagori; Hajime Yoshifuji; Takuma Oku; Chiyomi Sasaki; Hitomi Miyata; Keita P Mori; Toshiki Nakajima; Koichiro Ohmura; Daisuke Kawabata; Naoichiro Yukawa; Yoshitaka Imura; Kosaku Murakami; Ran Nakashima; Takashi Usui; Takao Fujii; Kaoru Sakai; Motoko Yanagita; Yoshitaka Hirayama; Tsuneyo Mimori
Journal:  PLoS One       Date:  2016-12-19       Impact factor: 3.240

3.  Renal protective effect of antiplatelet therapy in antiphospholipid antibody-positive lupus nephritis patients without antiphospholipid syndrome.

Authors:  Hironari Hanaoka; Harunobu Iida; Tomofumi Kiyokawa; Yukiko Takakuwa; Takahiro Okazaki; Hidehiro Yamada; Shoichi Ozaki; Kimito Kawahata
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

4.  Comparison of complete renal response and mortality in early- and late-onset lupus nephritis: a multicenter retrospective study of a Japanese cohort.

Authors:  Kunihiro Ichinose; Mineaki Kitamura; Shuntaro Sato; Keita Fujikawa; Yoshiro Horai; Naoki Matsuoka; Masahiko Tsuboi; Fumiaki Nonaka; Toshimasa Shimizu; Remi Sumiyoshi; Tomohiro Koga; Shin-Ya Kawashiri; Naoki Iwamoto; Takashi Igawa; Mami Tamai; Hideki Nakamura; Tomoki Origuchi; Tomoya Nishino; Atsushi Kawakami
Journal:  Arthritis Res Ther       Date:  2020-07-22       Impact factor: 5.156

5.  Comparison of the 2018 and 2003 International Society of Nephrology/Renal Pathology Society classification in terms of renal prognosis in patients of lupus nephritis: a retrospective cohort study.

Authors:  Ryosuke Umeda; Soshiro Ogata; Shigeo Hara; Kazuo Takahashi; Daijo Inaguma; Midori Hasegawa; Hidetaka Yasuoka; Yukio Yuzawa; Hiroki Hayashi; Naotake Tsuboi
Journal:  Arthritis Res Ther       Date:  2020-11-04       Impact factor: 5.156

6.  Outcomes of membranous and proliferative lupus nephritis - analysis of a single-centre cohort with more than 30 years of follow-up.

Authors:  Filipa Farinha; Ruth J Pepper; Daniel G Oliveira; Thomas McDonnell; David A Isenberg; Anisur Rahman
Journal:  Rheumatology (Oxford)       Date:  2020-11-01       Impact factor: 7.046

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.